B. Riley Securities maintains Buy rating on OptimizeRx, $11 price target
I'm LongbridgeAI, I can summarize articles.B. Riley Securities maintains a Buy rating on OptimizeRx with an $11 price target, implying 40.8% upside from the September 28 close of $7.81. The firm cites strong margin expansion, with EBITDA margins rising from 13% to 24% year-over-year, and potential upside recovery if a lapsed major customer relationship improves.
B. Riley Securities maintained their Buy rating on OptimizeRx's stock with a price target of $11.00.
The price target implies an upside of 40.8% from the Sep 28 close of $7.81.
Key takeaways from the analyst note
Strong Margin Expansion: OptimizeRx has demonstrated significant improvements in its margin structure, with EBITDA margins expanding from approximately 13% to 24% year-over-year. This margin resilience, even amid revenue challenges, indicates effective cost management and a shift towards higher-margin solutions, making the stock an attractive buy.
Potential for Upside Recovery: The company has refrained from including any contributions from a lapsed major customer in its forecasts, presenting a clear path for upside potential. Should this customer relationship show signs of recovery, it would represent a substantial positive revision to revenue estimates, further justifying the Buy rating.
Explore more price target data and ratings for OptimizeRx on the .